Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3729-3736

  Lin, Sue Hwa ^a,c   Lee, Yu Chen ^a   Choueiri, Michel B ^a   Wen, Sijin ^a   Mathew, Paul ^a   Ye, Xiangcang ^a   Do, Kim Anh ^a   Navone, Nora M ^a   Kim, Jeri ^a   Tu, Shi Ming ^a   Li YuanYu Lee, ^b   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 3; P45 SOLUBLE EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROSTATE SPECIFIC ANTIGEN; SOLUBLE EPIDERMAL GROWTH FACTOR RECEPTOR 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE DEVELOPMENT; BONE MARROW; BONE METASTASIS; BONE SCINTISCANNING; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; ILIAC CREST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PLASMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TUMOR GROWTH; BLOOD; BONE TUMOR; CANCER STAGING; DRUG EFFECT; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SOLUBILITY; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW; BONE NEOPLASMS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-3; SOLUBILITY; SURVIVAL ANALYSIS; TAXOIDS;

EID: 52449112465     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0472     Document Type: Article

References (29)

1. Jacobs SC. Spread of prostatic cancer to bone. Urology1983;21:337-44.
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
3. Smaletz 0, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972-82.
4. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16.
5. Gleave ME, Hsieh J-T, von Eschenbach AC, Chung LWK. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implication for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 1992;147:1151-9.
6. Yang J, Fizazi K, Peieg S, et al. Prostate cancer cells induce osteoblast differentiation through a cbfal-dependent pathway. Cancer Res 2001:61:5652-9.
7. Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 2003;97:772-8.
8. Logothetis C, Lin S-H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8.
9. Nelson JB, Hedican SP, George AH, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 1995;1:944-9.
10. Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002;62:917-23.
11. Barnes J, Anthony CT, Wall N, Steiner MS. Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 1995;13:337-43.
12. Hamdy FC, Autzen P, Robinson MC, Home CH, Neal DE, Robson CN. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 1997;57:4427-31.
13. 13.Vakar-Lopez F, Cheng C-J, Kim J, et al. Up-reg-ulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 2004;203:688-95.
14. Liang AK, Liu J, Mao SA. Siu VS, Lee YC, Lin SH. Expression of recombinant MDA-BF-1 with a kinase recognition site and a 7-histidine tag for receptor binding and purification. Protein Expr Purif 2005;44:58-64.
15. Chen N, Ye X-C, Chu K, et al. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 2007;67:1-5.
16. Mathew P.Thall PF, Bucana CD, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007;13:5816-24.
17. Fraley C, RafteryAE. Model-based clustering, discriminant analysis, and density estimation. J Am Stat Assoc 2002;97:611-31.
18. Lee H, Maihle NJ. Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues. Oncogene 1998;16:3243-52.
19. Nelson JB, Nguyen SH, Wu-Wong JR. et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999;53:1063-9.
20. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998:93:165-76.
21. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer Urology 2001;57:611-6.
22. Keller ET, Zhang J, Cooper CR, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone Cancer Metastasis Rev 2001;20:333-49.
23. Loberg RD, Logothetis CJ, Keller ET. Pienta KJ Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype J Clin Oncol 2005;23:8232-41.
24. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid J Clin Oncol 2005;23:4925-35
25. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases J Clin Oncol 2005;23:8219-24
26. Clarice NW, McClure J. George NJ. Morphometry evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80.
27. Crown J A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer Semin Oncol 1999;26:5-9.
28. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994:12:1232-7
29. Lee H, Akria RW. Sliwkowski MX, Maihle NJ A naturally occurring secreted human ErbB3 receptor iso-form inhibits heregulin-stimulated activation of ErbB2. ErbB3, and ErbB4 Cancer Res 2001;61:4467-73